Background: Coronary artery bypass grafting (CABG) is an effective method to afford sufficient blood flow for that ischemic myocardium. Off-pump coronary bypass surgery (OPCAB) has been rediscovered and refined to avoid cardiopulmonary bypass. However, it’s a high technique demanding skill. And evaluation of the blood flow should be reliable. Transit time flow measurement (TTFM) is introduced to evaluate graft flow and anastomosis patency intraoperatively. The accuracy of graft flow depends on how to explain the parameters of TTFM. Here, we introduce our experiences on the explanation of TTFM parameters.
Objective: We compared the graft patency of off-pump coronary artery bypass grafting with those of on-pump coronary artery bypass grafting by intraoperative transit time flow measurement (TTFM).
Methods: Three hundred patients were divided into off-pump group and on-pump group. TTFM was routinely performed for assessment of graft patency during operation. Revision of the grafts depends on the TTFM findings.
Results: One patient in OPCAB group was converted to conventional CABG group due to ventricular fibrillation. One patient died of multiple organ failure 21 days post-operation. Seven grafts were revised based on unsatisfactory TTFM findings. There was no statistical difference in the variables between the two groups except for anastmosis to right coronary artery.
Conclusions: Off-pump surgery can provide the same flow of grafts as that of on-pump surgery. TTFM is an effective tool to decide if a well-function graft is or not, and it allows for revision of failure graft during operation.
The chemokine C-C motif ligand 11, also known as eotaxin-1, has been identified as a novel mediator of inflammatory bone resorption. However, little is known regarding a potential role for CCL11/Eotaxin-1 in postmenopausal osteoporosis.
The scope of this study was to explore the relationship between serum CCL11/Eotaxin-1 concentrations and disease progression of postmenopausal females with osteoporosis.
A total of 83 postmenopausal women diagnosed with osteoporosis were enrolled. Meanwhile, 82 postmenopausal women with normal bone mineral density (BMD) and 85 healthy controls inner child-bearing age were enrolled as control. The Dual-energy X-ray absorptiometry was used to examine the BMDs at the femoral neck, lumbar spine 1-4 and total hip of all participants. Serum CCL11/Eotaxin-1 levels were examined by enzyme-linked immunosorbent assay. We also included inflammation marker interleukin-6 (IL-6) as well as a serum marker of bone resorption C-telopeptide cross-linked collagen type 1 (CTX-1). The Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI) were recorded to evaluate the clinical severity in POMP females.
Serum CCL11/Eotaxin-1 levels were significantly elevated in postmenopausal osteoporotic patients PMOP patients compared with PMNOP and healthy controls. We observed a significant negative correlation of serum CCL11/Eotaxin-1 levels with lumbar spine, femoral neck and total hip BMD. Furthermore, serum CCL11/ Eotaxin-1 concentrations were also positively related to the VAS and ODI scores. Last, serum CCL11/ Eotaxin-1 concentrations were positively associated with IL-6 and CTX-1 levels. These correlations remain significant after adjusting for age and BMI. Multivariate linear regression analysis demonstrated that CCL11/Eotaxin-1 could serve as an independent marker.
Serum CCL 11/Eotaxin-1 may serve as a candidate biomarker for postmenopausal osteoporosis. Therapeutics targeting CCL11/Eotaxin-1 and its related signalling way to prevent and slow progression of PMOP deserve further study.
In this paper a new wireless sensor network localization algorithm, based on a mobile beacon and TSVM (Transductive Support Vector Machines) is proposed, which is referred to as MTSVM. The new algorithm takes advantage of a mobile beacon to generate virtual beacon nodes and then utilizes the beacon vector produced by the communication between the nodes to transform the problem of localization into one of classification. TSVM helps to minimize the error of classification of unknown fixed nodes (unlabeled samples). An auxiliary mobile beacon is designed to save the large volumes of expensive sensor nodes with GPS devices. As shown by the simulation test, the algorithm achieves good localization performance.
Thyroid cancer is a very common form of endocrine system malignancy. To date, the molecular mechanism underlying thyroid cancer remains poorly understood. Studies of oncocytic tumors have led to a hypothesis which proposes that defects in oxidative phosphorylation (OX- PHOS) may result in a compensatory increase in mitochondrial replication and gene expression. As a result, mitochondrial DNA (mtDNA) mutation analysis has become a useful tool to explore the molecular basis of this disease. Among these mutations, mitochondrial transfer RNAs (mttRNAs) are the hot spots for pathogenic mutations associated with thyroid cancer. However, due to its high mutation rate, the role of mt-tRNA variants in thyroid cancer is still controversial. To address this problem, in this study, we reassessed seven reported mt-tRNA variants: tRNAAsp G7521A, tRNAArg T10411C and T10463C, tRNALeu(CUN) A12308G, tRNAIle G4292C and C4312T, and tRNAAla T5655C, in clinical manifestations of thyroid cancer. We first performed the phylogenetic conservation analysis for these variants; moreover, we used a bioinformatic tool to compare the minimum free energy (G) of mt-tRNA with and without mutations. Most strikingly, none of these variants caused the significant change of the G between the wild-type and the mutant form, suggesting that they may not play an important roles in thyroid cancer. In addition, we screened the frequency of the “pathogenic” A12308G alternation in 300 patients with thyroid cancer and 200 healthy controls. We found that there were five patients and three control subjects carrying this variant. It seemed that the A12308G variant may be a common polymorphism in the human population. Taken together, our study indicated that variants in mt-tRNA genes may not play active roles in patients with thyroid cancer.